CLINICAL_TRIALS
trial_result
· 2009-10-21
Clinical Trial Update: Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma [Phase 3]
Summary
Phase 3 trial evaluated RhuMab-E25 for reducing exhaled nitric oxide in allergic asthma; results were posted in 2009.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Duke University | Conditions: Allergic Asthma | Phase 3 | Status: COMPLETED | Results posted: 2009-10-21